Juniper Entered into an Exclusive License Agreement with Helsinn for Ledaga (chlormethine) to Treat Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma
Shots:
- The companies collaborated to register, distribute, promote, market, and sell Ledaga (chlormethine gel) in Australia, Asia, and the Middle East for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adults
- The collaboration helps to broaden the geographic distribution of Ledaga as a new treatment option to improve the lives of patients with cancer globally
- Additionally, Ledaga has been approved in multiple countries, incl. the EU & US, and was marketed under the trade names Ledaga and Valchlor. The EC has been approved Ledaga for the treatment of MF-CTCL in adult patients
Ref: PR Newswire | Image: Juniper
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
